AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11294487 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective Serotonin Reuptake Inhibitors (SSRIs)
Number of subjects: 0
Study 11294487 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic Antidepressants (TCAs)
Number of subjects: 0
Study 9405581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of [13C5] and [2H2]folic acid (approximately 500 nmol each)
Number of subjects: 4
Study 9405581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of [2H2]folic acid (226 nmol)
Number of subjects: 4
Study 9405581 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of [13C5]folic acid (1010 nmol)
Number of subjects: 4
Study 9405581 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intravenous vs oral doses
Number of subjects: 4
Study 8131770 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-NG (transdermal nitroglycerin) 10 mg.24 h-1
Number of subjects: 24
Study 8131770 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-NG + BNZ (benazepril 10 mg b.i.d.)
Number of subjects: 24
Study 8131770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3314877 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 53
Study 3314877 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support program
Number of subjects: 53
Study 3314877 — intervention group
Group type: COMPARATOR
Intervention: Control program (no adjunct treatment)
Number of subjects: 53
Study 31297739 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous repair with MitraClip®
Number of subjects: 921
Study 31297739 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy
Number of subjects: 921
Study 31297739 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter treatment with MitraClip®
Number of subjects: 921
Study 31297739 — intervention group
Group type: COMPARATOR
Intervention: Control group (optimal medical therapy)
Number of subjects: 921
Study 28075038 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (EX) for 24 weeks
Number of subjects: 19
Study 28075038 — intervention group
Group type: COMPARATOR
Intervention: Usual lifestyle control (CON)
Number of subjects: 19
Study 27125909 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol-10 (150 mg/day)
Number of subjects: 63
Study 27125909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 25336745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 92
Study 25336745 — intervention group
Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 92
Study 22219012 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional laparoscopic surgery (CLS)
Number of subjects: 90
Study 22219012 — intervention group
Group type: EXPERIMENTAL
Intervention: SPLS using one pre-bent and one straight laparoscopic instrument (SPLS-ps)
Number of subjects: 90
Study 22219012 — intervention group
Group type: EXPERIMENTAL
Intervention: SPLS using two pre-bent instruments (SPLS-pp)
Number of subjects: 90
Study 22219012 — intervention group
Group type: COMPARATOR
Intervention: SPLS (both groups)
Number of subjects: 90
Study 20527343 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 46
Study 20527343 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ropivacaine
Number of subjects: 46
Study 18606901 — intervention group
Group type: COMPARATOR
Intervention: Paricalcitol 0 microg (placebo)
Number of subjects: 24
Study 18606901 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol 1 microg
Number of subjects: 24
Study 18606901 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol 2 microg
Number of subjects: 24
Study 15682005 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom soft orthoses
Number of subjects: 404
Study 15682005 — intervention group
Group type: EXPERIMENTAL
Intervention: Semirigid biomechanical orthoses
Number of subjects: 404
Study 15682005 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple shoe inserts
Number of subjects: 404
Study 15682005 — intervention group
Group type: COMPARATOR
Intervention: Overall incidence of back pain
Number of subjects: 404
Study 12569288 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine (250 mg/m(2) days 1‐5 every 3 weeks) plus tamoxifen
Number of subjects: 125
Study 12569288 — intervention group
Group type: COMPARATOR
Intervention: Vindesine (3 mg/m(2) every week for 6 weeks, then every 2 weeks) plus tamoxifen
Number of subjects: 125
Study 10929906 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative hepatobiliary scintigraphy (QHBS)
Number of subjects: 20
Study 10929906 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincter of Oddi manometry (ESOM)
Number of subjects: 20
Study 10929906 — intervention group
Group type: COMPARATOR
Intervention: Control group (asymptomatic cholecystectomized patients)
Number of subjects: 20
Study 8794599 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 138
Study 8794599 — intervention group
Group type: COMPARATOR
Intervention: Lofepramine
Number of subjects: 138
Study 1352050 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride (150-300 mg daily)
Number of subjects: 62
Study 1352050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 1352050 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 62
Study 6371649 — intervention group
Group type: EXPERIMENTAL
Intervention: Bichromatic argon laser therapy (multiple wavelengths: 454.5 nm to 528.7 nm)
Number of subjects: 100
Study 6371649 — intervention group
Group type: EXPERIMENTAL
Intervention: Monochromatic argon laser therapy (green wavelength at 514.5 nm)
Number of subjects: 100
Study 6371649 — intervention group
Group type: COMPARATOR
Intervention: Comparison between bichromatic and monochromatic laser therapy
Number of subjects: 100
Study 3540025 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 45
Study 3540025 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 29744621 — intervention group
Group type: EXPERIMENTAL
Intervention: B-mode ultrasound
Number of subjects: 120
Study 29744621 — intervention group
Group type: EXPERIMENTAL
Intervention: RF echo tracking
Number of subjects: 120
Study 29744621 — intervention group
Group type: EXPERIMENTAL
Intervention: RF speckle probability distribution
Number of subjects: 120
Study 29126396 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured, individualized endurance training and nutrition education based on the Mediterranean diet for 3 months, plus monthly group training and regular telephone contact during the subsequent 9 months
Number of subjects: 68
Study 29126396 — intervention group
Group type: COMPARATOR
Intervention: Control group attended one session on healthy nutrition and the benefits of physical activity
Number of subjects: 68
Study 25930236 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Number of subjects: 751
Study 25930236 — intervention group
Group type: COMPARATOR
Intervention: Delayed partial intervention
Number of subjects: 751
Study 25930236 — intervention group
Group type: COMPARATOR
Intervention: ZDHS orphans
Number of subjects: 751
Study 25930236 — intervention group
Group type: COMPARATOR
Intervention: All orphan groups
Number of subjects: 751
Study 24157432 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training during hemodialysis (40 min/session for 3 months)
Number of subjects: 35
Study 24157432 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training during hemodialysis
Number of subjects: 35
Study 21426751 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD) group (25 patients, 20M/5F, mean age 61.2 ± 10.4 years)
Number of subjects: 45
Study 21426751 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-CAD group (20 patients, 8M/12F, mean age 57.8 ± 13.3 years)
Number of subjects: 45
Study 18510068 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltrative anesthesia using 2% lidocaine with adrenaline (1:200,000)
Number of subjects: 58
Study 18510068 — intervention group
Group type: COMPARATOR
Intervention: No local infiltrative anesthesia with adrenaline (Control)
Number of subjects: 58
Study 16513672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrabrachial infusions of noradrenaline (NA)
Number of subjects: 19
Study 16513672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrabrachial infusions of tyramine (TYR)
Number of subjects: 19
Study 11983727 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (2-2.5 mg patches/d)
Number of subjects: 67
Study 11983727 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 67
Study 9806692 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumide
Number of subjects: 36
Study 9806692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8552887 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2714912 — intervention group
Group type: EXPERIMENTAL
Intervention: oral atenolol (100 mg per day)
Number of subjects: 43
Study 2714912 — intervention group
Group type: EXPERIMENTAL
Intervention: oral verapamil (80 mg three times per day)
Number of subjects: 43
Study 318849 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine, etidocaine, and bupivacaine in 10-ml doses of plain solutions
Number of subjects: 67
Study 318849 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 67
Study 31320738 — intervention group
Group type: EXPERIMENTAL
Intervention: ranibizumab treatment
Number of subjects: 367
Study 29969750 — intervention group
Group type: EXPERIMENTAL
Intervention: Pheochromocytoma
Number of subjects: 295
Study 29969750 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest urinary normetanephrine quartile
Number of subjects: 295
Study 29969750 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing urinary normetanephrine quartile categories
Number of subjects: 295
Study 27740883 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention (CBI)
Number of subjects: 0
Study 27740883 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 25439413 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 4 mg (Group O4)
Number of subjects: 135
Study 25439413 — intervention group
Group type: COMPARATOR
Intervention: ramosetron 0.3 mg (Group R)
Number of subjects: 135
Study 25439413 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg (Group O8)
Number of subjects: 135
Study 22475819 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher net endogenous acid production
Number of subjects: 632
Study 22475819 — intervention group
Group type: EXPERIMENTAL
Intervention: Net endogenous acid production
Number of subjects: 632
Study 20560920 — intervention group
Group type: EXPERIMENTAL
Intervention: Intersurgical Solus laryngeal mask airway (LMA)
Number of subjects: 120
Study 20560920 — intervention group
Group type: COMPARATOR
Intervention: i-gel
Number of subjects: 120
Study 18391564 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical ear canal stimulation (ECS)
Number of subjects: 18
Study 18391564 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative residual hearing (nonamplified and amplified)
Number of subjects: 18
Study 15908851 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone or audio computer‐assisted self‐interview (ACASI)
Number of subjects: 588
Study 15908851 — intervention group
Group type: EXPERIMENTAL
Intervention: Asking about future intentions before asking about the behavior
Number of subjects: 588
Study 12952109 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 460
Study 12952109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 10336575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 10 mg
Number of subjects: 24
Study 10336575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 20 mg
Number of subjects: 24
Study 10336575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mizolastine 40 mg
Number of subjects: 24
Study 10336575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7577307 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention
Number of subjects: 381
Study 7577307 — intervention group
Group type: COMPARATOR
Intervention: Standard intervention
Number of subjects: 381
Study 2044648 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine (24 g daily in divided doses) plus moderate cholesterol-lowering diet
Number of subjects: 3806
Study 2044648 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus moderate cholesterol-lowering diet
Number of subjects: 3806
Study 7006620 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg xipamide per day
Number of subjects: 30
Study 7006620 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg xipamide per day
Number of subjects: 30
Study 7006620 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of xipamide
Number of subjects: 30
Study 29460509 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxytherapy in Group IA (AA patients)
Number of subjects: 80
Study 29460509 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxytherapy in Group IIA (AGA patients)
Number of subjects: 80
Study 29460509 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Group IB (AA patients)
Number of subjects: 80
Study 29460509 — intervention group
Group type: COMPARATOR
Intervention: Placebo in Group IIB (AGA patients)
Number of subjects: 80
Study 27876079 — intervention group
Group type: EXPERIMENTAL
Intervention: Circle of Security-Parenting (COS-P)
Number of subjects: 314
Study 27876079 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 314
Study 24833263 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric training (CON)
Number of subjects: 22
Study 24833263 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training (ECC)
Number of subjects: 22
Study 22720051 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice‐weekly, school‐based jumping regime
Number of subjects: 29
Study 22720051 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 20042191 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Lys:Arg ratio diet (0.7)
Number of subjects: 30
Study 20042191 — intervention group
Group type: COMPARATOR
Intervention: High Lys:Arg ratio diet (1.4)
Number of subjects: 30
Study 18811118 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen cross-linking (CXL) with 0.1% riboflavin and UVA irradiation (370 nm, 3 mW/cm2, 30 min)
Number of subjects: 49
Study 18811118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 49
Study 16043121 — intervention group
Group type: EXPERIMENTAL
Intervention: CXCR3 polymorphism c.12+234G > A
Number of subjects: 0
Study 12455115 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ropivacaine without adrenalin but with 10 U/mL of hyaluronidase (Group RH)
Number of subjects: 100
Study 12455115 — intervention group
Group type: COMPARATOR
Intervention: 1% ropivacaine without adrenalin and without hyaluronidase (Group R)
Number of subjects: 100
Study 10744344 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 30 IU/kg bodyweight
Number of subjects: 9
Study 10744344 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 60 IU/kg bodyweight
Number of subjects: 9
Study 10744344 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO 100 IU/kg bodyweight
Number of subjects: 9
Study 10744344 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (all doses)
Number of subjects: 9
Study 8905242 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 500 mg
Number of subjects: 5
Study 8905242 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 750 mg
Number of subjects: 5
Study 8905242 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1000 mg
Number of subjects: 5
Study 8905242 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1250 mg
Number of subjects: 5
Study 8905242 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 1500 mg
Number of subjects: 5
Study 1648944 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bolus infusion of metoclopramide (1 mg/kg, 30 min, every 8 h, day 1-5)
Number of subjects: 21
Study 1648944 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of metoclopramide (3 mg/kg/24 h, 120 h)
Number of subjects: 21
Study 1648944 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of metoclopramide
Number of subjects: 21
Study 1648944 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus infusion of metoclopramide
Number of subjects: 21
Study 7136436 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic bladder drainage using an indwelling Silastic catheter
Number of subjects: 0
Study 7136436 — intervention group
Group type: COMPARATOR
Intervention: Transurethral catheterization
Number of subjects: 0
Study 7136436 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic bladder drainage
Number of subjects: 0
Study 31970581 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived drug-related stigma measures
Number of subjects: 241
Study 31970581 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalized drug-related stigma measures
Number of subjects: 241
Study 31970581 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-related stigma
Number of subjects: 241
Study 31970581 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-related stigma
Number of subjects: 241
Study 30790587 — intervention group
Group type: EXPERIMENTAL
Intervention: DSAEK with preoperative ECD
Number of subjects: 1007
Study 30790587 — intervention group
Group type: EXPERIMENTAL
Intervention: DSAEK with ECD at 6 months
Number of subjects: 1007
Study 30790587 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative complications during DSAEK
Number of subjects: 1007
Study 30790587 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft dislocation during DSAEK
Number of subjects: 1007
Study 28131045 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (2.7 g/d)
Number of subjects: 154
Study 28131045 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (2.7 g/d)
Number of subjects: 154
Study 28131045 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (3 g/d)
Number of subjects: 154
Study 27004292 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Loading (IL)
Number of subjects: 30
Study 27004292 — intervention group
Group type: COMPARATOR
Intervention: Delayed Loading (DL)
Number of subjects: 30
Study 24961021 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4
Number of subjects: 50
Study 24961021 — intervention group
Group type: COMPARATOR
Intervention: 3% modified fluid gel
Number of subjects: 50
Study 22226431 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical eflornithine hydrochloride
Number of subjects: 27
Study 22226431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 20074751 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin‐A subtype receptor antagonist sitaxsentan at 1 mg/kg
Number of subjects: 29
Study 20074751 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin‐A subtype receptor antagonist sitaxsentan at 2 mg/kg
Number of subjects: 29
Study 20074751 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (saline)
Number of subjects: 29
Study 17684988 — intervention group
Group type: EXPERIMENTAL
Intervention: Agents containing succinic and fumaric acids (Group 1, n = 11)
Number of subjects: 22
Study 17684988 — intervention group
Group type: COMPARATOR
Intervention: Infusion therapy (Group 2, n = 11)
Number of subjects: 22
Study 16229647 — intervention group
Group type: EXPERIMENTAL
Intervention: 405 nm violet diode laser (continuous on-axis)
Number of subjects: 0
Study 16229647 — intervention group
Group type: COMPARATOR
Intervention: 670 nm red diode laser (continuous on-axis)
Number of subjects: 0
Study 16229647 — intervention group
Group type: EXPERIMENTAL
Intervention: 405 nm violet diode laser (flickering or off-axis)
Number of subjects: 0
Study 16229647 — intervention group
Group type: COMPARATOR
Intervention: 670 nm red diode laser (flickering or off-axis)
Number of subjects: 0
Study 16229647 — intervention group
Group type: EXPERIMENTAL
Intervention: 405 nm violet diode laser (eccentric targets)
Number of subjects: 0
Study 16229647 — intervention group
Group type: COMPARATOR
Intervention: 670 nm red diode laser (eccentric targets)
Number of subjects: 0
Study 11874928 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dietary and exercise program
Number of subjects: 79
Study 11874928 — intervention group
Group type: COMPARATOR
Intervention: Modest dietary and exercise program (control)
Number of subjects: 79
Study 10201429 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory guided saccades
Number of subjects: 1
Study 10201429 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory guided pointing
Number of subjects: 1
Study 8499823 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin once daily
Number of subjects: 157
Study 8499823 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethylpenicillin three or four times a day
Number of subjects: 157
Study 3306508 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonist
Number of subjects: 4
Study 3306508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31729550 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose fentanyl infusion (1 mcg/kg/hr)
Number of subjects: 58
Study 31729550 — intervention group
Group type: COMPARATOR
Intervention: 24% oral sucrose (2 ml)
Number of subjects: 58
Study 30377118 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise for 30 min at 30 min after dinner
Number of subjects: 15
Study 30377118 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise for 30 min at 60 min after dinner
Number of subjects: 15
Study 27405296 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin/laropiprant (ERN/LRPT)
Number of subjects: 796
Study 27405296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 796
Study 25440230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (geographically isolated EDs)
Number of subjects: 307